SCU-CUHK Joint Laboratory for Reproductive Medicine, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu 610041, People's Republic of China.
Prenatal Diagnosis Center, Department of Obstetrics & Gynecologic, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu 610041, People's Republic of China.
Leuk Res. 2019 Nov;86:106225. doi: 10.1016/j.leukres.2019.106225. Epub 2019 Sep 13.
Our previous studies have demonstrated that a previously unrecognized role of CFTR in hematopoiesis and acute leukemia. Here, we show that CFTR inhibitor CFTR-inh172 possesses ability to inhibit human T-cell acute lymphoblastic leukemia cells. In detail, CFTR-inh172 inhibited cell proliferation, promoted apoptosis and arrested the cell cycle in human T-cell acute lymphoblastic leukemia cell CCRF-CEM, JURKAT and MOLT-4. Furthermore, transcriptome analysis reveals that CFTR-inh172 induces significant alteration of gene expression related to apoptosis and proliferation. These findings demonstrate the potential of CFTR inhibitor CFTR-inh172 in human T-cell acute lymphoblastic leukemia treatment.
我们之前的研究表明，CFTR 在造血和急性白血病中具有以前未被认识到的作用。在这里，我们表明 CFTR 抑制剂 CFTR-inh172 具有抑制人 T 细胞急性淋巴细胞白血病细胞的能力。具体来说，CFTR-inh172 抑制细胞增殖，促进细胞凋亡并使人类 T 细胞急性淋巴细胞白血病细胞 CCRF-CEM、JURKAT 和 MOLT-4 细胞周期停滞。此外，转录组分析表明，CFTR-inh172 诱导与细胞凋亡和增殖相关的基因表达的显著改变。这些发现表明 CFTR 抑制剂 CFTR-inh172 在人 T 细胞急性淋巴细胞白血病治疗中的潜力。
